Monopar Therapeutics Stock Analysis

Monopar Stock Analysis Notes

About 37.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 1.98. Monopar Therapeutics had not issued any dividends in recent years. The entity had 1:5 split on the 13th of August 2024. Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 9 people. To find out more about Monopar Therapeutics contact MBA MD at 847 388 0349 or learn more at https://www.monopartx.com.

Monopar Therapeutics Investment Alerts

Monopar Therapeutics Upcoming and Recent Events

Monopar Largest EPS Surprises

View All Earnings Estimates

Monopar Therapeutics Environmental, Social, and Governance (ESG) Scores

Monopar Therapeutics Thematic Classifications

Monopar Stock Institutional Investors

Note, although Monopar Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Monopar Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 189.85 M.

Monopar Profitablity

Management Efficiency

Monopar Therapeutics has return on total asset (ROA) of (0.5967) % which means that it has lost $0.5967 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1204) %, meaning that it created substantial loss on money invested by shareholders. Monopar Therapeutics' management efficiency ratios could be used to measure how well Monopar Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 02/26/2025, Return On Tangible Assets is likely to drop to -1.38. In addition to that, Return On Capital Employed is likely to grow to -1.73. At this time, Monopar Therapeutics' Total Assets are relatively stable compared to the past year. As of 02/26/2025, Total Current Assets is likely to grow to about 11.2 M, while Non Current Assets Total are likely to drop slightly above 10.8 K.

Technical Drivers

As of the 26th of February, Monopar Therapeutics secures the Mean Deviation of 5.81, downside deviation of 8.34, and Risk Adjusted Performance of 0.1351. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Monopar Therapeutics, as well as the relationship between them. Please verify Monopar Therapeutics standard deviation, value at risk, as well as the relationship between the Value At Risk and kurtosis to decide if Monopar Therapeutics is priced some-what accurately, providing market reflects its recent price of 35.99 per share. Given that Monopar Therapeutics has jensen alpha of 1.35, we recommend you to check Monopar Therapeutics's last-minute market performance to make sure the company can sustain itself at a future point.

Monopar Therapeutics Price Movement Analysis

Monopar Therapeutics Insider Trading Activities

Monopar Therapeutics Outstanding Bonds

Monopar Therapeutics Predictive Daily Indicators

Monopar Therapeutics Corporate Filings

Monopar Therapeutics Forecast Models

Monopar Therapeutics' time-series forecasting models are one of many Monopar Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Monopar Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Monopar Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Monopar shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Monopar Therapeutics. By using and applying Monopar Stock analysis, traders can create a robust methodology for identifying Monopar entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Monopar analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Monopar analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Monopar Therapeutics stock analysis indicators help investors evaluate how Monopar Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Monopar Therapeutics shares will generate the highest return on investment. By understating and applying Monopar Therapeutics stock analysis, traders can identify Monopar Therapeutics position entry and exit signals to maximize returns.

When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.